GSK confident it can prevail in vaccine battle

GSK's battle to win over the $2 billion market for cervical cancer vaccines has experienced a few big setbacks. French health officials are now recommending against paying for Cervarix and the FDA has lingered long over GSK's application for approval. But Glaxo U.S. pharma chief Chris Viehbacher (photo) insists in a talk with the Wall Street Journal that all is well. Viehbacher says that at the end of the day, head-to-head study data will prove too compelling for the regulators on both sides of the Atlantic to ignore. Meanwhile, though, Merck's Gardasil continues to solidify its position in the market.

- read the report in the Wall Street Journal

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.